Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
“The data that will be presented at AACR provide evidence for AU-011’s activity in tumors that express specifically modified heparan-sulfate proteoglycans on the tumor cell surface. Activity was observed in every tumor type tested, indicating that there are numerous solid tumors we can consider to expand the clinical development of AU-011, including those derived from neural or epithelial lineages,” said Dr.
Details for the poster presentation are as follows:
Title: Biological Assessment of the Virus-Like Drug Conjugate AU-011 to Specifically Target a Breadth of Human Cancer Types
Poster Session: ETO1 Drug Discovery
Date and time:
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Discovery
Abstract Number: 5331
For more information, visit aurabiosciences.com, or follow Aura on Twitter and LinkedIn.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward looking statements. Words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions that can be used to identify forward-looking statements. These forward looking statements include express or implied statements regarding Aura’s future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of AU-011 for the treatment of a number of solid tumor types and expectations with respect to any future clinical trials and clinical development plans for AU-011.
The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Aura’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura’s clinical trials may not be predictive of future results in connection with future clinical trials; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Aura’s business, operations, strategy, goals and anticipated timelines; Aura’s ongoing and planned pre-clinical activities; and Aura’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading “Risk Factors” in Aura’s most recent Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006137/en/
Investor and Media Contact:
212-600-1902 | firstname.lastname@example.org